Eszopiclone + Fluoxetine + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sleep Initiation and Maintenance Disorders
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Trial Timeline
Oct 1, 2005 → Dec 1, 2008
NCT ID
NCT00247624About Eszopiclone + Fluoxetine + Placebo
Eszopiclone + Fluoxetine + Placebo is a approved stage product being developed by Sumitomo Pharma for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00247624. Target conditions include Sleep Initiation and Maintenance Disorders, Depression.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00247624 | Approved | Completed |
Competing Products
20 competing products in Sleep Initiation and Maintenance Disorders